Shareholders at Arbutus Biopharma (NASDAQ: ABUS) approve 2026 share plan and auditor
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Arbutus Biopharma Corporation reported results from its 2026 Annual General and Special Meeting of Shareholders. Shareholders approved the new 2026 Omnibus Share and Incentive Plan, which authorizes issuance of an aggregate 16,300,000 common shares to support future equity-based compensation.
All director nominees were elected with strong majorities. Shareholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers and ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 5.07, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
2026 Plan share authorization: 16,300,000 common shares
Votes for 2026 Plan: 138,877,189 votes for
Votes against 2026 Plan: 7,408,185 votes against
+3 more
6 metrics
2026 Plan share authorization
16,300,000 common shares
Aggregate shares authorized for issuance under 2026 Omnibus Share and Incentive Plan
Votes for 2026 Plan
138,877,189 votes for
Shareholder approval of 2026 Omnibus Share and Incentive Plan
Votes against 2026 Plan
7,408,185 votes against
Shareholder approval of 2026 Omnibus Share and Incentive Plan
Say-on-pay support
137,629,207 votes for
Advisory vote on named executive officer compensation
Auditor ratification votes for
164,372,596 votes for
Appointment of Ernst & Young LLP as 2026 independent auditor
Director votes for Roger Sawhney
139,299,405 votes for
Election of director nominee Roger Sawhney, MD
Key Terms
2026 Omnibus Share and Incentive Plan, Management Proxy Circular and Proxy Statement, non-binding advisory basis, broker non-votes, +1 more
5 terms
Management Proxy Circular and Proxy Statement regulatory
"set forth in the Company’s Management Proxy Circular and Proxy Statement filed with the U.S. Securities and Exchange Commission"
non-binding advisory basis financial
"approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers"
A non-binding advisory basis is guidance or a recommendation offered for informational purposes that does not create legal obligations or guarantees; recipients can accept, modify, or ignore it without contractual consequences. Investors should treat it like a weather forecast for planning—useful for forming expectations and assessing risk, but not a firm promise—so they should verify assumptions, seek confirming information, and avoid relying on it as the sole basis for investment decisions.
broker non-votes financial
"Votes For | Votes Against | Votes Abstained | Broker Non-Votes 138,877,189 | 7,408,185 | 188,253 | 22,829,831"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"approved the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
FAQ
Were Arbutus Biopharma’s director nominees elected at the 2026 meeting?
Yes. Each Arbutus Biopharma director nominee, including Lindsay Androski, Robert Alan Beardsley, Joseph Bishop, Matthew Gline, and Roger Sawhney, received between 126,670,273 and 139,299,405 votes for, with relatively smaller withheld votes and 22,829,831 broker non-votes reported for each nominee.
What were the say-on-pay results for Arbutus Biopharma (ABUS) executives in 2026?
On a non-binding advisory basis, shareholders approved the compensation of Arbutus Biopharma’s named executive officers, with 137,629,207 votes for, 8,331,760 against, 512,660 abstentions, and 22,829,831 broker non-votes. This indicates general shareholder support for the disclosed executive pay program.
Which audit firm will serve Arbutus Biopharma (ABUS) for fiscal 2026?
Shareholders approved the appointment of Ernst & Young LLP as Arbutus Biopharma’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 164,372,596 votes for, 2,123,916 against, and 2,806,946 abstentions reported in the vote tally.